Spruce Biosciences says FDA pre-BLA meetings support TA-ERT filing in Q4 2026

Reuters2026/08/24 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Spruce Biosciences completed two pre-BLA meetings with the FDA for TA-ERT in Sanfilippo syndrome type B.
BLA submission remains on track for Q4 2026, using the accelerated approval pathway based on reduction in CSF HS-NRE.
FDA backed the CMC comparability approach following manufacturing technology transfer, supporting the planned filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Spruce Biosciences says FDA pre-BLA meetings support TA-ERT filing in Q4 2026

You may also like

Crypto prices